Search
Research
Early life innate immune signatures of persistent food allergyEarly life innate immune dysfunction may represent a key immunological driver and predictor of persistent food allergy in childhood
Research
Pertussis immunisation in infancy and atopic outcomes: A protocol for a population-based cohort study using linked administrative dataThe burden of IgE-mediated food allergy in Australian born children is reported to be among the highest globally. This illness shares risk factors and frequently coexists with asthma, one of the most common noncommunicable diseases of childhood.
Research
Early introduction of food reduces food allergy – Pro and ConWhen an infant is developmentally ready, a variety of nutritious foods should be introduced including the ‘more allergenic’ foods during infancy
Research
Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infantsThe purpose of this article is to highlight emerging evidence for existing allergy prevention guidelines regarding potential benefits of supporting early...
Research
EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergyFood allergy can have significant effects on morbidity and quality of life and can be costly in terms of medical visits and treatments.
Research
Food AllergyFood allergies have become more common in our community, with up to one in ten young children now affected. Reactions can range from mild hives to life threatening anaphylaxis and breathing difficulties. The most common food allergies are to egg, peanut, tree nuts, cow’s milk, fish, shellfish, sesame, wheat and soy.
News & Events
Back to school anxiety: How to help your child transition into the new school yearAs we count down to the end of the long summer holidays, it’s natural for children to feel anxious about what the new school year will bring.
News & Events
Cow’s milk protein allergies on the rise in our kidsUp to three out of every 100 babies develop cow's milk protein allergy (CMPA) in their first year of life – and this number appears to be on the rise
Research
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEThe pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.
Research
Identifying gene network patterns and associated cellular immune responses in children with or without nut allergyAlthough evidence suggests that the immune system plays a key role in the pathophysiology of nut allergy, the precise immunological mechanisms of nut allergy have not been systematically investigated. The aim of the present study was to identify gene network patterns and associated cellular immune responses in children with or without nut allergy.